Advicenne Stock

Advicenne Equity

The The Equity of Advicenne (ALDVI.PA) as of Aug 8, 2026 is -19.07 M EUR. In the previous year, The Equity was -12.61 M EUR — a change of 51.25% (lower).

Equity

-19.07 MEUR

YoY

51.25%

Last updated:

In 2026, Advicenne's equity was -19.07 M EUR, a 51.25% increase from the -12.61 M EUR equity in the previous year.

Access this data via the Eulerpool API

Advicenne Stock analysis

What does Advicenne do? Advicenne SA is a French pharmaceutical company specializing in the development of medications for rare and chronic diseases. The company was founded in 2007 by Dr. Luc-André Granier and is headquartered in Nîmes, France. Business model Advicenne develops its products based on proven technologies in the pharmaceutical industry. The company specializes in the development of medications for rare and chronic diseases, particularly for patients with kidney and metabolic disorders. The company implements a customer-oriented development strategy and is committed to close collaboration with doctors and patients. Advicenne has entered into various partnerships and licensing agreements with other pharmaceutical companies to distribute and further develop its products and technologies worldwide. Divisions Advicenne operates in various business areas, including the development of medications for kidney and metabolic disorders, as well as the marketing of products for patients with chronic diseases. Product portfolio The company currently offers three products: 1. Sibnayal: Sibnayal is a medication for the treatment of kidney diseases. It has been developed to prevent the disease-related loss of potassium in patients with kidney failure. The medication is currently approved for use in a clinical trial. 2. ADV7103: ADV7103 is a medication for the treatment of metabolic disorders. It has been developed to help patients with metabolic disorders such as phenylketonuria (PKU) and hypervalinemia (HV). The medication is currently approved under the name Orladeyo™ and is marketed in collaboration with Daiichi Sankyo Company, Limited. 3. ADV6209: ADV6209 is a medication for the treatment of chronic pain. It is targeted at patients who have not found sufficient pain relief due to chronic pain. The medication is currently in phase II of clinical trials. Advicenne has made significant investments in the development of innovative medications in recent years and has expanded its product pipeline to improve the therapeutic options for patients with rare and chronic diseases. Conclusion Advicenne is an emerging company in the pharmaceutical industry that focuses on the development of medications for rare and chronic diseases. The company aims to improve the lives of patients with its therapies and is committed to close collaboration with doctors and patients. Advicenne has already brought several promising products to market and continues to heavily invest in research and development to improve the therapeutic options for patients with rare and chronic diseases. Advicenne is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Advicenne's Equity

Advicenne's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Advicenne's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Advicenne's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Advicenne's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Advicenne’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Advicenne stock

The Equity of Advicenne is -19.07 M EUR in 2026.

The Equity of Advicenne changed from -12.61 M EUR to -19.07 M EUR, representing a 51.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Advicenne since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Advicenne historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Advicenne

All Key Metrics — Advicenne